$2.63 Billion is the total value of Tekla Capital Management LLC's 222 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 15.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VRTX | Sell | Vertex Pharmaceuticals Inc. | $138,574,000 | +19.9% | 477,330 | -1.7% | 5.27% | +0.9% |
| GILD | Sell | Gilead Sciences, Inc. | $121,644,000 | -13.8% | 1,581,026 | -16.3% | 4.63% | -27.5% |
| JNJ | Sell | Johnson & Johnson | $116,727,000 | +6.1% | 830,031 | -1.0% | 4.44% | -10.6% |
| ILMN | Sell | Illumina, Inc. | $79,496,000 | +9.7% | 214,651 | -19.1% | 3.03% | -7.6% |
| MRK | Sell | Merck & Co., Inc. | $75,126,000 | -4.5% | 971,496 | -5.0% | 2.86% | -19.6% |
| BIIB | Sell | Biogen Inc. | $62,499,000 | -40.6% | 233,599 | -29.8% | 2.38% | -50.0% |
| PFE | Sell | Pfizer Inc. | $54,169,000 | -8.8% | 1,656,548 | -9.0% | 2.06% | -23.2% |
| ALXN | Sell | Alexion Pharmaceuticals, Inc. | $43,180,000 | +16.3% | 384,709 | -6.9% | 1.64% | -2.1% |
| TMO | Sell | Thermo Fisher Scientific Inc. | $38,417,000 | +20.9% | 106,025 | -5.4% | 1.46% | +1.8% |
| LLY | Sell | Eli Lilly and Co. | $33,958,000 | -5.4% | 206,837 | -20.0% | 1.29% | -20.3% |
| INCY | Sell | Incyte Corp. | $33,796,000 | +6.8% | 325,053 | -24.8% | 1.29% | -10.1% |
| BMRN | Sell | BioMarin Pharmaceutical Inc. | $30,263,000 | +32.3% | 245,362 | -9.3% | 1.15% | +11.4% |
| ISRG | Sell | Intuitive Surgical, Inc. | $18,998,000 | +12.7% | 33,339 | -2.1% | 0.72% | -5.1% |
| ALNY | Sell | Alnylam Pharmaceuticals, Inc. | $18,642,000 | +24.4% | 125,867 | -8.5% | 0.71% | +4.9% |
| CI | Sell | Cigna Corp. | $15,010,000 | -40.6% | 79,988 | -43.9% | 0.57% | -50.0% |
| NVS | Sell | Novartis AGsponsored adr | $14,936,000 | +0.7% | 171,008 | -4.9% | 0.57% | -15.2% |
| TECH | Sell | Bio-Techne Corp. | $13,655,000 | +24.8% | 51,710 | -10.4% | 0.52% | +5.1% |
| AZN | Sell | AstraZeneca PLCsponsored adr | $12,418,000 | +0.7% | 234,798 | -15.0% | 0.47% | -15.1% |
| IDXX | Sell | IDEXX Laboratories, Inc. | $12,221,000 | +25.1% | 37,014 | -8.2% | 0.46% | +5.4% |
| ZTS | Sell | Zoetis Inc.class a | $11,117,000 | -37.8% | 81,121 | -46.6% | 0.42% | -47.6% |
| ANTM | Sell | Anthem, Inc. | $10,583,000 | -28.9% | 40,242 | -38.6% | 0.40% | -40.1% |
| ALLO | Sell | Allogene Therapeutics, Inc. | $9,252,000 | +94.9% | 216,069 | -11.5% | 0.35% | +63.7% |
| BPMC | Sell | Blueprint Medicines Corp. | $9,224,000 | +13.2% | 118,256 | -15.1% | 0.35% | -4.6% |
| ASND | Sell | Ascendis Pharma A/Ssponsored adr | $8,502,000 | +8.9% | 57,482 | -17.1% | 0.32% | -8.2% |
| FOLD | Sell | Amicus Therapeutics, Inc. | $5,082,000 | +49.1% | 336,984 | -8.7% | 0.19% | +25.3% |
| GBT | Sell | Global Blood Therapeutics, Inc. | $4,530,000 | -24.9% | 71,759 | -39.2% | 0.17% | -37.0% |
| ABMD | Sell | ABIOMED, Inc. | $3,815,000 | -11.0% | 15,794 | -46.5% | 0.14% | -25.3% |
| GWPH | Sell | GW Pharmaceuticals plcads | $3,074,000 | -29.9% | 25,051 | -50.0% | 0.12% | -40.9% |
| BHVN | Sell | Biohaven Pharmaceutical Holding Company Ltd. | $2,506,000 | +63.0% | 34,277 | -24.1% | 0.10% | +37.7% |
| AVDL | Sell | Avadel Pharmaceuticals plcsponsored adr | $1,888,000 | -58.0% | 233,612 | -58.7% | 0.07% | -64.5% |
| GMAB | Sell | Genmab A/Ssponsored ads | $560,000 | -82.2% | 16,520 | -88.8% | 0.02% | -85.2% |
| ABIO | Sell | ARCA biopharma, Inc. | $215,000 | +115.0% | 32,461 | -10.0% | 0.01% | +60.0% |
| QHCCQ | Exit | Quorum Health Corporation | $0 | – | -23,725 | -100.0% | 0.00% | – |
| VIE | Exit | Viela Bio, Inc. | $0 | – | -500 | -100.0% | -0.00% | – |
| MRUS | Exit | Merus N.V. | $0 | – | -21,215 | -100.0% | -0.01% | – |
| HQY | Exit | HealthEquity, Inc. | $0 | – | -27,310 | -100.0% | -0.06% | – |
| RARX | Exit | Ra Pharmaceuticals, Inc. | $0 | – | -35,743 | -100.0% | -0.08% | – |
| AGN | Exit | Allergan plcshares | $0 | – | -157,981 | -100.0% | -1.26% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Gilead Sciences, Inc. | 41 | Q2 2023 | 12.4% |
| Amgen, Inc. | 41 | Q2 2023 | 5.8% |
| Biogen Inc. | 41 | Q2 2023 | 6.5% |
| Vertex Pharmaceuticals Incorporated | 41 | Q2 2023 | 5.3% |
| Regeneron Pharmaceuticals, Inc. | 41 | Q2 2023 | 9.1% |
| Illumina, Inc. | 41 | Q2 2023 | 3.4% |
| BioMarin Pharmaceutical Inc. | 41 | Q2 2023 | 2.9% |
| Teva Pharmaceutical Industries Ltd. | 41 | Q2 2023 | 3.2% |
| Neurocrine Biosciences, Inc. | 41 | Q2 2023 | 1.4% |
| McKesson Corporation | 41 | Q2 2023 | 2.2% |
View Tekla Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rallybio Corp | January 23, 2023 | 1,727,067 | 4.6% |
| Zyla Life SciencesSold out | January 29, 2021 | 0 | 0.0% |
| ARCA biopharma, Inc. | January 24, 2020 | 36,068 | 2.3% |
| Verona Pharma plc | February 12, 2019 | 5,296,845 | 4.9% |
| Alliqua BioMedical, Inc. | February 12, 2018 | 165,000 | 3.3% |
| PIERIS PHARMACEUTICALS, INC. | February 12, 2018 | 1,962,380 | 4.4% |
| Intellipharmaceutics International Inc. | February 13, 2015 | 2,184,000 | 9.0% |
| HERON THERAPEUTICS, INC. /DE/ | February 14, 2014 | 20,598,613 | 4.2% |
| MEDWAVE INC | February 14, 2012 | 1,277,372 | 9.8% |
| MZT Holdings, Inc. | February 14, 2012 | 2,553,420 | 4.0% |
View Tekla Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-10 |
| SC 13G/A | 2023-01-23 |
| 13F-HR | 2022-11-01 |
| 13F-HR | 2022-07-29 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| SC 13G | 2022-01-21 |
| 13F-HR | 2021-11-12 |
View Tekla Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.